Fears Of Recession Mount As Coronavirus Declared A Pandemic
Biopharma Determined To Maintain Clinical Trials, Drug Launches
Executive Summary
Investor sentiment still backing growth for pharma and biotech sectors, but the length and severity of COVID-19's impact globally has yet to be seen.
You may also be interested in...
Antibodies Taken From Recovered Coronavirus Patient Could Yield Therapies
Funded by the US government since March 2018, the Vancouver-based company aims to have an antibody therapy ready for clinical trials within four months.
Investor Faith In David Hung’s Nuvation Renewed By Anheart Buyout
The acquisition brings two potential best-in-class cancer therapies, which could make Nuvation a commercial company as soon as 2025.
Vertex Joins Regulus In Kidney Disease Therapy Hunt
The Boston, MA biotech is about to enter the clinic with its autosomal dominant polycystic kidney disease candidate but microRNA therapy pioneer Regulus is already setting the pace.